Format

Send to

Choose Destination
Joint Bone Spine. 2015 Oct;82 Suppl 1:eS17-29. doi: 10.1016/S1297-319X(15)30004-X.

Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases.

Author information

1
Medical Doctor; Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin - Buch, Berlin, Germany.
2
Rheumatologist, Rheumatology Department, Centro Hospitalar, Universitario de Coimbra, Coimbra, Portugal.
3
Medical Doctor, Department of Rheumatology, Hospital Garcia de 'Orta, Lisbon, Portugal; University Hospital of Alexandroupolis, Alexandroupolis, Greece.
4
Rheumatologist, First Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
5
Professor of Internal Medicine, First Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
6
Head, Department of Nephrology and Dialysis, Ospedale AUSL "Guglielmo da Saliceto", Piacenza, Italy.
7
Deputy Director, Immanuel Krankenhause Berline Medical Centre for Rheumatology Berlin - Buch, Berlin, Germany. Electronic address: w.schmidt@immanuel.de.
8
Assistant Professor of Internal Medicine, First Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.

Abstract

A subgroup of patients with gouty arthritis have a chronic recurring form that is particularly difficult to treat. Such patients experience repeated flares and often have abundant tophi. Many also have underlying comorbidities, such as renal impairment, cardiovascular disease, gastrointestinal disorders, obesity, and hypertension, which contraindicate the use of standard anti-inflammatory medications. Five patients with difficult to treat gouty arthritis who were either candidates and/or treated with anti-IL therapy are described.

KEYWORDS:

Anakinra; Anti-IL-1β therapy; Canakinumab; Gouty arthritis; Tophaceous gout

PMID:
26717798
DOI:
10.1016/S1297-319X(15)30004-X
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center